Dallah Healthcare Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Dallah Healthcare yıllık ortalama 25.5% oranında kazançlarını artırırken, Healthcare sektöründe kazançlar growing at 20.3% annual. Gelirler growing yılda ortalama 21.5% oranında artmaktadır. Dallah Healthcare'in özkaynak karlılığı 12.9% ve net marjı 14.3%'dir.
Anahtar bilgiler
25.5%
Kazanç büyüme oranı
23.1%
EPS büyüme oranı
| Healthcare Sektör Büyümesi | 12.3% |
| Gelir büyüme oranı | 21.5% |
| Özkaynak getirisi | 12.9% |
| Net Marj | 14.3% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Some Shareholders Feeling Restless Over Dallah Healthcare Company's (TADAWUL:4004) P/E Ratio
Oct 31
The Return Trends At Dallah Healthcare (TADAWUL:4004) Look Promising
Oct 07Do Dallah Healthcare's (TADAWUL:4004) Earnings Warrant Your Attention?
Sep 19Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 14The Price Is Right For Dallah Healthcare Company (TADAWUL:4004)
Jul 18Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist
May 30We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease
Apr 16What You Can Learn From Dallah Healthcare Company's (TADAWUL:4004) P/E
Mar 18Returns On Capital At Dallah Healthcare (TADAWUL:4004) Have Hit The Brakes
Feb 25Dallah Healthcare (TADAWUL:4004) Has More To Do To Multiply In Value Going Forward
Oct 30Dallah Healthcare (TADAWUL:4004) Is Reinvesting At Lower Rates Of Return
Jul 26Returns On Capital Signal Tricky Times Ahead For Dallah Healthcare (TADAWUL:4004)
Apr 17Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?
Feb 06Dallah Healthcare (TADAWUL:4004) Will Want To Turn Around Its Return Trends
Dec 05We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease
Nov 01Calculating The Intrinsic Value Of Dallah Healthcare Company (TADAWUL:4004)
Aug 28Dallah Healthcare (TADAWUL:4004) Has Some Way To Go To Become A Multi-Bagger
Aug 12Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching
Jul 28Industry Analysts Just Upgraded Their Dallah Healthcare Company (TADAWUL:4004) Revenue Forecasts By 10%
May 26Calculating The Fair Value Of Dallah Healthcare Company (TADAWUL:4004)
May 20Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching
Apr 16Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Feb 03Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?
Jan 10Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Oct 19Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Jul 09Forecast: Analysts Think Dallah Healthcare Company's (TADAWUL:4004) Business Prospects Have Improved Drastically
Jun 16Broker Revenue Forecasts For Dallah Healthcare Company (TADAWUL:4004) Are Surging Higher
May 02What Kind Of Shareholders Hold The Majority In Dallah Healthcare Company's (TADAWUL:4004) Shares?
Mar 17Has Dallah Healthcare (TADAWUL:4004) Got What It Takes To Become A Multi-Bagger?
Mar 02Dallah Healthcare (TADAWUL:4004) Shareholders Booked A 45% Gain In The Last Year
Feb 15Should You Buy Dallah Healthcare Company (TADAWUL:4004) For Its Dividend?
Feb 01Are Dallah Healthcare's (TADAWUL:4004) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 05
Dallah Healthcare Company's (TADAWUL:4004) Intrinsic Value Is Potentially 26% Below Its Share Price
Dec 22Will Dallah Healthcare (TADAWUL:4004) Multiply In Value Going Forward?
Nov 20Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Dallah Healthcare nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 3,105 | 444 | 580 | 0 |
| 31 Mar 24 | 3,010 | 385 | 565 | 0 |
| 31 Dec 23 | 2,943 | 360 | 549 | 0 |
| 30 Sep 23 | 2,831 | 325 | 537 | 0 |
| 30 Jun 23 | 2,682 | 270 | 487 | 0 |
| 31 Mar 23 | 2,595 | 286 | 456 | 0 |
| 31 Dec 22 | 2,488 | 274 | 443 | 0 |
| 30 Sep 22 | 2,370 | 305 | 464 | 0 |
| 30 Jun 22 | 2,313 | 311 | 450 | 0 |
| 31 Mar 22 | 2,220 | 289 | 434 | 0 |
| 31 Dec 21 | 2,105 | 259 | 416 | 0 |
| 30 Sep 21 | 1,935 | 202 | 402 | 0 |
| 30 Jun 21 | 1,742 | 206 | 371 | 0 |
| 31 Mar 21 | 1,498 | 165 | 331 | 0 |
| 31 Dec 20 | 1,318 | 132 | 307 | 0 |
| 30 Sep 20 | 1,257 | 150 | 277 | 0 |
| 30 Jun 20 | 1,207 | 123 | 272 | 0 |
| 31 Mar 20 | 1,246 | 131 | 287 | 0 |
| 31 Dec 19 | 1,252 | 147 | 286 | 0 |
| 30 Sep 19 | 1,227 | 110 | 304 | 0 |
| 30 Jun 19 | 1,206 | 115 | 295 | 0 |
| 31 Mar 19 | 1,193 | 119 | 293 | 0 |
| 31 Dec 18 | 1,181 | 142 | 286 | 0 |
| 30 Sep 18 | 1,189 | 172 | 281 | 0 |
| 30 Jun 18 | 1,203 | 217 | 274 | 0 |
| 31 Mar 18 | 1,218 | 268 | 260 | 0 |
| 31 Dec 17 | 1,212 | 295 | 246 | 0 |
| 30 Sep 17 | 1,202 | 284 | 254 | 0 |
| 30 Jun 17 | 1,180 | 268 | 265 | 0 |
| 31 Mar 17 | 1,181 | 252 | 275 | 0 |
| 31 Dec 16 | 1,163 | 225 | 288 | 0 |
| 30 Sep 16 | 1,122 | 228 | 264 | 0 |
| 30 Jun 16 | 1,073 | 194 | 255 | 0 |
| 31 Mar 16 | 1,030 | 175 | 249 | 0 |
| 31 Dec 15 | 985 | 165 | 231 | 0 |
| 30 Sep 15 | 948 | 161 | 219 | 0 |
| 30 Jun 15 | 917 | 156 | 211 | 0 |
| 31 Mar 15 | 892 | 154 | 206 | 0 |
| 31 Dec 14 | 859 | 147 | 201 | 0 |
| 30 Sep 14 | 831 | 149 | 203 | 0 |
| 30 Jun 14 | 805 | 149 | 194 | 0 |
| 31 Mar 14 | 773 | 138 | 184 | 0 |
| 31 Dec 13 | 750 | 137 | 182 | 0 |
Kaliteli Kazançlar: 4004 yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: 4004 'nin mevcut net kar marjları (14.3%) geçen yılın (10.1%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 4004 şirketinin kazançları son 5 yılda yılda 25.5% oranında önemli ölçüde arttı.
Büyüme Hızlandırma: 4004 'un son bir yıldaki kazanç büyümesi ( 64.3% ) 5 yıllık ortalamasını (yıllık 25.5% ) aşıyor.
Kazançlar vs. Sektör: 4004 geçen yılki kazanç büyümesi ( 64.3% ) Healthcare sektörünün 13.5% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: 4004 'nin Özsermaye Getirisi ( 12.9% ) düşük olarak değerlendiriliyor.